Previous 10 | Next 10 |
Expanding portfolio with first internally discovered asset in Inflammation and Immunology with internally discovered asset A highly selective, allosteric TYK2 inhibitor that has shown potent inhibition against pro-inflammatory cytokines in preclinical studies BeiGene...
Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November
The PD-1 blocker market has exploded into place as one of the most important and promising major biopharma oncology markets yet to appear. Immuno-oncology drugs that block the checkpoint PD-1 have been some of the most successful stories in the industry over recent years, launching blockbuste...
BRUKINSA is now approved for the treatment of MCL in 11 countries and regions, including the United States, China, Canada, Australia, Brazil, the United Arab Emirates, and Russia BeiGene and NewBridge Pharmaceuticals are working together to rapidly advance BRUKINSA in the Midd...
LianBio raised $325 million in its NASDAQ IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma completed a $260 million IPO in Hong Kong and will use the proceeds to continue development of Trimer-Tag vaccines, Trimer-Tag...
BeiGene (NASDAQ:BGNE): Q3 GAAP EPS of -$4.46 beats by $0.58. Revenue of $192.46M (+111.3% Y/Y) beats by $6.2M. Press Release For further details see: BeiGene EPS beats by $0.58, beats on revenue
Recorded product revenue of $192.5 million for the third quarter, representing a 111% increase from $91.1 million in the prior year period Received approvals for BRUKINSA ® in two new indications in the U.S. and approvals in six other markets Submitted first...
First presentation of SEQUOIA results reports BRUKINSA’s superiority over chemoimmunotherapy in patients with treatment-naïve chronic lymphocytic leukemia Results from SEQUOIA in frontline CLL and the positive ALPINE trial in the relapsed or refractory setting supp...
This marks the first regulatory approval for BRUKINSA in Russia BRUKINSA is now approved for the treatment of MCL in ten countries, following the U.S., China, Canada, Australia, and others BeiGene is committed to rapidly advancing the global registration of BRUKINS...
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. The $1.4 billion landmark deal between Beijing's BeiGene and Celgene (now Bristol-Myers) is falling apart. The companies are arguing over BeiGene's C...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...